Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

BACKGROUND: To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribas, Antoni, Kirkwood, John M, Atkins, Michael B, Whiteside, Theresa L, Gooding, William, Kovar, Andreas, Gillies, Stephen D, Kashala, Oscar, Morse, Michael A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724499/
https://www.ncbi.nlm.nih.gov/pubmed/19640287
http://dx.doi.org/10.1186/1479-5876-7-68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724499/
https://www.ncbi.nlm.nih.gov/pubmed/19640287
http://dx.doi.org/10.1186/1479-5876-7-68

Ejemplares similares